-
"Diversity, Equity and Inclusion" Page Renewal
Introducing Eisai DE&I: Now and the Future
Learn more
"Diversity, Equity and Inclusion" Page Renewal
Introducing Eisai DE&I: Now and the Future
-
Looking Back on 10 Years Since the Commencement of Free Provision of DEC Tablets
Eisai Staff in Charge Talks About Overcoming Challenges on the Uneven Road by Building Trust in Global Partnerships
-
Scientists Discuss the Development of a New Treatment for the Elimination of Mycetoma
-
New Innovation Page Launch
-
May 15, 2024
-
May 15, 2024
-
May 15, 2024
-
May 15, 2024
-
May 13, 2024
-
May 17, 2024
IR “Annual Financial Results Briefing for the Fiscal Year Ended March 31, 2024 [Material, Webcast]”
-
May 15, 2024
IR “Annual Financial Report for the Fiscal Year Ended March 31, 2024”
-
May 7, 2024
Recent hhc Activities “Let‘s Learn More about Cancer Patients”
-
April 26, 2024
Sustainability "Eisai India’s Initiatives for Eliminating Lymphatic Filariasis"
-
March 27, 2024
-
April 8, 2024
-
October 13, 2023
-
March 9, 2023
Warning Against Solicitation, Fraudulent Emails, etc. that Use the Name of Eisai or Related Parties
-
February 17, 2023
EISAI SUPPORTS RELIEF EFFORTS FOR EARTHQUAKE IN TURKEY AND SYRIA
-
July 15, 2022
Notification Regarding U.S. Research and Development Subsidiary
Sustainability
30 countries 2.28 billion tablets
Number of countries supplied with lymphatic filariasis treatment
and volume supplied (as of March 2024)
Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries